Cancer immunotherapy is the most dynamically developing field of cancer pharmacotherapy. It involves activation of the patient’s immune system to fight cancer and create long-term immune memory to prevent relapses and metastases. One of the immune activation strategies is to change the nature of the tumour microenvironment by reducing local concentrations of immunosuppressive metabolites or blocking their effects in immune cells. Adenosine is a key immunometabolite that induces immune tolerance in the tumour. It is present in healthy tissues at low concentrations, performing different physiological functions. In the cancer, its concentration increases rapidly, due to overexpression of adenosine-producing enzymes, exacerbated by hypoxia and inflammation. The aim of the project is to develop and implement Selvita S.A.'s own activity, characterised at the level of phase I of a candidate for a new generation oncology drug. The proposed strategy envisages working on three therapeutic objectives in the preclinical phase: enzymes of adenosine-producing metabolic pathway (CD73/CD39) and adenosine receptor A2A/B. This will allow the selection of a clinical candidate with the greatest therapeutic potential, the greatest chances of success in clinical trials and partnering with a pharmaceutical company. Molecular targets developed in the substance design give a high probability of getting a first-in-class drug (CD73/CD39) or best in its class (A2A/B). As a result, Selvita will introduce one or more experimental drug candidates into its activities. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014).